Eli Lilly and Company, has become a member of SAFE-BioPharma Association, the non-profit association that created and manages the global SAFE-BioPharma™ digital identity and signature standard for the pharmaceutical and healthcare industries. Lilly joins numerous other major biopharmaceutical companies that are using the SAFE-BioPharma standard to manage identities of employees and external collaborators. As a member, Lilly employees and others associated with the organization will be able to utilize SAFE-BioPharma digital signatures to sign a broad variety of documents. Lilly also will have access to the SAFE-BioPharma Certification Bridge Authority, a system that leverages the efficiencies and cost-savings of the Internet by allowing its users to trust identities in online transactions. Because SAFE-BioPharma is linked to the Federal Bridge, Internet transmissions between SAFE-BioPharma members and federal agencies are trusted and accepted. This capability saves money and greatly reduces identity theft. “Following extensive examination of the benefits of SAFE-BioPharma membership, member companies decide to join so they can enjoy the substantial cost-savings and efficiencies that the SAFE-BioPharma standard delivers to the biopharmaceutical industry. We look forward to helping Lilly get the greatest benefit from its membership,” said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association. The SAFE-BioPharma standard was established by the biopharmaceutical industry to help it transform to a fully electronic environment from inefficient paper-based business and regulatory processes. SAFE-BioPharma provides a high level of trust assurance for digital identities, which are uniquely bound to corresponding digital signatures.
